






What science can do

AstraZeneca Annual Report and Form 20-F Information 2015




AstraZeneca at a glance

AstraZeneca is a global, science-led biopharmaceutical business...
...with an on-market portfolio in our chosen therapy areas.

Respiratory, Inflammation and Autoimmunity	Cardiovascular and Metabolic diseases	Oncology	Infection, Neuroscience and Gastrointestinal
			
\$4,987m	\$9,489m	\$2,825m	\$6,340m
Product Sales 2014: \$5,063m 2013: \$4,677m	Product Sales 2014: \$9,802m 2013: \$8,830m	Product Sales 2014: \$3,027m 2013: \$3,193m	Product Sales 2014: \$8,203m 2013: \$9,011m
Highlights			
<ul style="list-style-type: none"> > Respiratory sales up by 7%, including 25% in Emerging Markets, before completion of the acquisition of Takeda's respiratory business > Sales of <i>Symbicort</i> down by 3% 	<ul style="list-style-type: none"> > <i>Brilinta/Brilique</i> sales up by 44%, including 64% in the US > Diabetes sales up by 26%, including 76% in Emerging Markets > Sales of <i>Crestor</i> fell by 3% reflecting competition from generic statins and pricing pressure 	<ul style="list-style-type: none"> > Oncology sales up by 7% > New Oncology included for the first time (comprising <i>Lynparza</i>, <i>Iressa</i> (US) and <i>Tagrisso</i>) > <i>Lynparza</i> launched in 15 markets and sales of \$94 million 	<ul style="list-style-type: none"> > Sales of <i>Nexium</i> declined by 26%, including 52% in the US following loss of exclusivity > Sales of <i>Seroquel XR</i> fell by 12% and <i>Synagis</i> fell by 26%

 Sales and Marketing from page 48, Financial Review from page 62 and Geographical Review from page 227

We have distinctive R&D capabilities, a growing late-stage pipeline...



NMEs in Phase III, pivotal Phase II or under regulatory review

15

 Therapy Area Review from page 24 and Research and Development from page 42

2015		15
2014		13
2013		11
2012		6

...and a strong global commercial presence, with strength in Emerging Markets.

North America	Europe	International and Japan
\$10,007m Product Sales 2014: \$10,710m 2013: \$10,328m	\$5,323m Product Sales 2014: \$6,638m 2013: \$6,658m	\$8,311m Product Sales 2014: \$8,747m 2013: \$8,725m
7,600	5,900	21,900
Highlights		
<ul style="list-style-type: none"> > Sales in the US declined by 6% reflecting entry of generic <i>Nexium</i> products and adverse <i>Synagis</i> guideline changes > Favourable performances were delivered by <i>Brilinta</i>, <i>Farxiga</i>, <i>Bydureon</i> and <i>Lynparza</i> as well as the acquired Respiratory medicines, <i>Tudorza</i> and <i>Daliresp</i> > Sales in Canada grew by 4% 	<ul style="list-style-type: none"> > Sales declined by 6% > Strong growth for Diabetes medicines was offset by generic competition facing <i>Crestor</i> and <i>Seroquel XR</i> > 14% decline in <i>Symbicort</i> sales reflected adverse pricing movements driven by competition from analogues in key markets 	<ul style="list-style-type: none"> > Emerging Markets revenue grew by 12% to \$5,822 million, including China sales growth of 15% > Sales in Japan grew by 4% to \$2,020 million > Opened facility in Russia

 Business Review from page 42

Our talented employees are committed to achieving our Purpose in a sustainable way...

61,500
employees worldwide






8,900
employees in R&D



12,500
employees in Manufacturing and Supply



Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres



 Employees from page 52

...and our disciplined capital allocation enables commitment to a progressive dividend.

\$3,443m

Net cash shareholder distributions
increased to \$3,443 million

2015		\$3,443m
2014		\$3,242m
2013		\$2,979m

\$2.80

Dividend per Ordinary Share
unchanged

2015		\$2.80
2014		\$2.80
2013		\$2.80

All growth rates at CER.
All employee numbers are approximate as at 31 December 2015.